Stocks rise and fall for many reasons, but abnormal movements are often associated with earnings announcements. Turns out that yesterday, Illumina announced Q3 2020 earnings, which is probably why their stock fell -4.6%.
Full Answer
Is there “there there” in Illumina’s stock price drop?
When the size of a stock’s drop exceeds the broader market’s drop, then there may be some “there there.” Yesterday, Illumina stock fell just over -7% at market closing price. Let’s adjust this first:
Should you hold Illumina (ilmn) stock?
The consensus among Wall Street analysts is that investors should "hold" Illumina stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ILMN, but not buy additional shares or sell existing shares. View analyst ratings for Illumina or view top-rated stocks.
Why has Illumina performed so well over the years?
Looking at Illumina’s 10-Q SEC filing reminds us of why this company has performed so well over the years. Incredibly, over 70% of Illumina’s revenues came from consumables.
What are analysts'target prices for Illumina's stock?
13 equities research analysts have issued 1-year target prices for Illumina's stock. Their predictions range from $280.00 to $370.00. On average, they expect Illumina's stock price to reach $328.7273 in the next twelve months.
Why are Illumina Shares down?
The gene-sequencing supplier Illumina delivered on its March quarter financial forecasts, as global demand for genetically-informed cancer treatment made up for Covid lockdowns at China's labs, but Wall Street analysts cut their forecasts for the stock price regardless.
Is Illumina a good buy?
Currently, Illumina, Inc.'s price-earnings ratio is 44.5. Illumina, Inc.'s trailing 12-month revenue is $4.7 billion with a 15.0% profit margin. Year-over-year quarterly sales growth most recently was 11.9%. Analysts expect adjusted earnings to reach $4.128 per share for the current fiscal year.
Is Illumina undervalued?
Illumina retains a regular Real Value of $261.82 per share. The prevalent price of the firm is $194.88. At this time, the firm appears to be undervalued....USD 194.88 9.31 4.56%LowTarget PriceHigh340.00440.36570.00
Does Illumina stock pay dividends?
ILMN Illumina, Inc. ILMN does not currently pay a dividend.
Should I buy or sell Illumina stock?
Is Illumina stock A Buy? Illumina holds several negative signals and is within a wide and falling trend, so we believe it will still perform weakly in the next couple of days or weeks. We therefore hold a negative evaluation of this stock.
Is Illumina a good long term investment?
Illumina is a good long-term investment since its projects and research will take time to realize returns when its products and patents make their way into the market. Speculators should avoid the stock as it tends to exhibit short-term fluctuation.
Who owns Illumina?
Francis deSouzaIllumina, Inc.TypePublicKey peopleFrancis deSouza (President & CEO) John W. Thompson ( Board Chair) Sam Samad (CFO)ProductsNovaSeq 6000, HiSeq X, HiSeq 4000, MiSeq, MiSeqDx, MiniSeq, iSeq 100, NextSeq 550, NextSeq 550Dx, iScanRevenueUS$4.53 billion (2021)Operating incomeUS$−0.12 billion (2021)12 more rows
How do I invest in Illumina?
How to buy Illumina Stocks & Shares to Invest in ILMN Steps of buying Illumina sharesStep 1: find a good online broker. ... Step 2: open your brokerage account. ... Step 3: deposit money to your account. ... Step 4: buy the Illumina share. ... Step 5: review your Illumina position regularly.
Will Illumina buy Grail?
Despite facing backlash from global powers, Illumina completed its acquisition of Grail in August 2021. The U.S. Federal Trade Commission began suing Illumina to stop the deal, which is still an ongoing ordeal within the courts.
Is Illumina a buy Zacks?
Zacks' proprietary data indicates that Illumina, Inc. is currently rated as a Zacks Rank 3 and we are expecting an inline return from the ILMN shares relative to the market in the next few months.
Should I sell ILMN?
Out of 8 analysts, 2 (25%) are recommending ILMN as a Strong Buy, 0 (0%) are recommending ILMN as a Buy, 5 (62.5%) are recommending ILMN as a Hold, 0 (0%) are recommending ILMN as a Sell, and 1 (12.5%) are recommending ILMN as a Strong Sell.
Can I buy Grail stock?
If Grail goes public independently, you'll be able to buy shares after the IPO happens. You can also buy shares of Illumina now — though it's unclear whether Illumina's acquisition of Grail will hold. Compare share trading platforms.
Is Illumina a buy right now?
9 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Illumina in the last twelve months. There are currently...
When is Illumina's next earnings date?
Illumina is scheduled to release its next quarterly earnings announcement on Thursday, August 4th 2022. View our earnings forecast for Illumina .
How were Illumina's earnings last quarter?
Illumina, Inc. (NASDAQ:ILMN) issued its earnings results on Thursday, May, 5th. The life sciences company reported $1.07 EPS for the quarter, beati...
What guidance has Illumina issued on next quarter's earnings?
Illumina updated its FY 2022 earnings guidance on Monday, May, 23rd. The company provided earnings per share guidance of $4.00-$4.20 for the period...
What price target have analysts set for ILMN?
9 equities research analysts have issued 12-month price objectives for Illumina's stock. Their forecasts range from $325.00 to $520.00. On average,...
Who are Illumina's key executives?
Illumina's management team includes the following people: Mr. Francis A. deSouza , CEO & Director (Age 51) ( LinkedIn Profile ) Mr. Sam A. Samad...
What is Francis deSouza's approval rating as Illumina's CEO?
496 employees have rated Illumina CEO Francis deSouza on Glassdoor.com . Francis deSouza has an approval rating of 92% among Illumina's employees....
Who are some of Illumina's key competitors?
Some companies that are related to Illumina include Thermo Fisher Scientific (TMO) , Agilent Technologies (A) , Mettler-Toledo International (MT...
What other stocks do shareholders of Illumina own?
Based on aggregate information from My MarketBeat watchlists, some companies that other Illumina investors own include NVIDIA (NVDA) , Alibaba Gr...
How much of Illumina's revenue comes from consumables?
Incredibly, over 70% of Illumina’s revenues came from consumables. Also known as the “razor and blades model,” these business models work well when consumables are high-margin products, and Illumina is no exception with 2019 gross margins nearing 70%. Illumina’s basic financials – Credit: Yahoo Finance.
How much did Illumina buy Grail?
This past September, Illumina shares tumbled -7.5% when they announced plans to buy Grail for $3.5 billion in cash and $4.5 billion in shares, a price tag that investors may have thought was too rich. ( Illumina plans to raise $1 billion in capital through debt ...
About Illumina
Illumina, Inc. engages in the development, manufacturing, and marketing of life science tools and integrated systems for large-scale analysis of genetic variation and function.
Headlines
Illumina vs. Qiagen: Which Diagnostics & Research Stock is a Better Buy?
Illumina (NASDAQ:ILMN) Frequently Asked Questions
10 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Illumina in the last year. There are currently 1 sell rating, 7 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" Illumina stock.
How much did Boston Scientific grow in revenue?
1. Revenue Growth. Between 2017 and 2020, Boston Scientific’s revenues grew by about 10% from $9.0 billion in 2017 to $9.9 billion in 2020. Note that 2020 revenues declined 7% y-o-y due to the impact of the pandemic on the company’s business.
Will Boston Scientific see a rebound in 2021?
However, we believe that this gap will narrow going forward in favor of Boston Scientific. While business for both the companies have been hit during the pandemic, due to deferment of elective surgeries, it is expected to see a sharp rebound in 2021, with containment of the Covid-19 virus.
Is Illumina better than Boston Scientific?
Now, Illumina’s operating margin has been better than Boston Scientific over the last twelve month period as well as over the recent years.
What happened?
Healthcare giant Illumina ( NASDAQ:ILMN) reported its second-quarter financial results after the market closed on Thursday. The company's update showed that its performance during the period came short of expectations. As a result, investors are selling off shares of Illumina today, and its stock is down by 13.1% as of 12:51 p.m. EDT.
So what
During the second quarter, Illumina recorded revenue of $633 million -- a 25% year-over-year decrease -- which is what analysts were expecting on average. Also, the company recorded a non-GAAP (adjusted) net income of $92 million, or $0.62 on a per-share basis.
Now what
The COVID-19 pandemic will continue to present serious obstacles to Illumina. However, the genome sequencing market is ripe for growth, and Illumina is one of the leaders in this market. The healthcare company is poised to rebound once the crisis subsides, which means now may be a good opportunity to purchase its shares.
Top Research Reports for Merck, Shopify & Intercontinental Exchange
Today's Research Daily features new research reports on 16 major stocks, including Merck & Co., Inc. (MRK), Shopify Inc. (SHOP), and Intercontinental Exchange, Inc. (ICE).
Bionano Stock Looks to Have a Monster Comeback in Its Future
Bionano (NASDAQ:BNGO) stock has tumbled, but it will come back big. Source: Dennis Diatel / Shutterstock.com As Cathie Wood and many others know, owning growth stocks over the last year has not been easy.
Illumina's (ILMN) GRAIL, Point32Health Unite to Offer MCED Test
Illumina's (ILMN) GRAIL Galleri MCED test detects more than 50 types of cancer and can predict the origin of the cancer signal with high accuracy across multiple cancer types.
NASDAQ:ILMN
Global leader in DNA sequencing. Almost 90% recurring revenue with good growth. Highly cash generative with good balance sheet. Good acquirer. Expects DNA sequencing will be a pervasive treatment option in healthcare. (Analysts’ price target is $404.80)
What is Illumina Inc. stock symbol?
Illumina Inc. is a American stock, trading under the symbol ILMN-Q on the NASDAQ (ILMN). It is usually referred to as NASDAQ:ILMN or ILMN-Q
Is Illumina Inc. a buy or a sell?
In the last year, 1 stock analyst published opinions about ILMN-Q. 1 analyst recommended to BUY the stock. 0 analysts recommended to SELL the stock. The latest stock analyst recommendation is . Read the latest stock experts' ratings for Illumina Inc..
Is Illumina Inc. a good investment or a top pick?
Illumina Inc. was recommended as a Top Pick by on . Read the latest stock experts ratings for Illumina Inc..
Why is Illumina Inc. stock dropping?
Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.
Is Illumina Inc. worth watching?
1 stock analyst on Stockchase covered Illumina Inc. In the last year. It is a trending stock that is worth watching.
Illumina Stock Dives On Grail Takeover
The saga to acquire Grail has been riddled with drama. Illumina founded Grail in 2016 and soon after spun it off into an independent company. Grail makes a variety of tests to detect cancer in a patient's blood. Last year, Illumina announced its plan to buy Grail for roughly $8 billion.
Analyst Remains Bullish On Deal
Canaccord's Mikson remained bullish on Illumina stock and the Grail deal.
